Ocular Therapeutix Posts $94.8M Q3 Loss, NDA on Track

Ocular Therapeutix (NASDAQ: OCUL) reported a third-quarter 2026 net loss of $94.8 million, or $0.42 per share, on November 9, 2026, versus a $69.4 million loss a year earlier, while holding $530.6 million in cash and guiding to runway into 2028. The Bedford, Massachusetts-based retina company said its AXPAXLI wet AMD New Drug Application remains on track for a fourth-quarter 2026 submission under the 505(b)(2) pathway, contingent on an interim SOL-R Week 52 safety analysis due the same quarter.

Context — why the AXPAXLI NDA timing matters now

The company said it completed a positive Pre-NDA Meeting with the FDA in September 2026, its latest in a series of regulatory interactions that included a Special Protocol Assessment for SOL-1 and Type C meetings. Ocular said those discussions reaffirmed alignment on the submission package.

That matters because the planned filing rests on SOL-1 Week 52 efficacy data, combined SOL-1 and interim SOL-R Week 52 safety data, plus confirmatory evidence. The interim SOL-R safety readout is therefore the gate: the company said it will bring the aggregate safety dataset above 300 patients with at least one year of follow-up, in line with FDA requirements.

Ocular said the 505(b)(2) route has the potential to shorten FDA review by up to 60 days versus the traditional 505(b)(1) pathway for a new molecular entity. The company also intends to submit data from subjects who received multiple AXPAXLI injections across both Phase 3 trials, aiming to support repeat dosing on the label if approved.

For a pre-revenue commercial-stage biotech, that pathway choice and the safety dataset size are the two variables that determine how quickly a filing converts into an approval decision. The company said its three wet AMD trials serve distinct objectives: SOL-1 showed superiority to a single aflibercept 2 mg injection, SOL-R tests non-inferiority to Q8W aflibercept 2 mg, and SOL-X evaluates 48-week dosing.

Data — what the Q3 numbers show

The quarter's revenue and spending lines moved in opposite directions. Total net revenue was $12.9 million, down from $14.5 million in the comparable 2025 quarter. Research and development expenses rose to $74.8 million from $52.4 million, which the company attributed to faster enrollment in HELIOS-3 and SOL-X plus added headcount and infrastructure.

Metric	Q3 2026	Q3 2025
Total net revenue	$12.9M	$14.5M
Research and development	$74.8M	$52.4M
Selling and marketing	$15.7M	$13.1M
General and administrative	$18.8M	$16.0M
Net loss	$(94.8)M	$(69.4)M
Net loss per share	$(0.42)	$(0.38)

Selling and marketing climbed to $15.7 million from $13.1 million, reflecting personnel and pre-commercial investment ahead of a potential AXPAXLI wet AMD launch. General and administrative costs rose to $18.8 million from $16.0 million on higher personnel costs and infrastructure to support a wider clinical scope and manufacturing expansion.

Cash and cash equivalents stood at $530.6 million as of September 30, 2026, with roughly 220.0 million shares outstanding as of November 6, 2026. The company said its runway projection covers SOL-1 completion and continued execution of SOL-R, SOL-X and HELIOS-3, plus pre-commercial investment. It excludes the full expense Ocular expects for scaling manufacturing capacity and its commercial team if approved.

Analysis — what the loss and the pipeline mean for OCUL holders

The widening loss is a function of trial scale, not revenue deterioration alone. R&D consumed $74.8 million in a single quarter against $12.9 million of revenue, so the cash balance is the metric that matters most for equity holders. At the current burn, the $530.6 million covers the planned NDA submission, the interim SOL-R safety analysis, and pre-launch commercial build-out through 2028, per the company.

The company's own limitation disclosure is the key risk: the runway excludes full manufacturing scale-up and commercial team costs. A launch would require additional capital, and the company did not disclose how it intends to fund that gap.

On the clinical side, Ocular presented SOL-1 post-hoc analyses at the 2026 AAO Annual Meeting and the Empire Forum. The AAO analysis reported that 71% of AXPAXLI-treated subjects were quantitatively dry at Week 8 using an AI-based measure detecting trace fluid, and roughly 70% of those stayed dry through Week 36 after a single injection. The Empire Forum analysis reported 28% of AXPAXLI-treated SOL-1 subjects had early persistent fluid, defined as a central subfield thickness change above 30 micrometres at Week 8, and those subjects had worse visual outcomes and a 32-week earlier time to first supplemental injection.

Ocular said preliminary SOL-R screening data show about 20% of otherwise eligible subjects were excluded for early persistent fluid or fluid variability, matching its pre-trial expectations from historical literature. Positioning here is a binary regulatory trade: holders are long the NDA and the SOL-R design, while the counter-argument is that SOL-R efficacy data are not required for the filing and topline results are not due until the first quarter of 2028.

The company also said it moved the SOL-R primary endpoint to Week 40 from Week 56, with key secondary endpoints retained at Weeks 56 and 96. It said the change was necessary to preserve the integrity of the masked trial by ensuring all subjects passed the new primary endpoint visit before the interim Week 52 safety analysis.

Outlook — what to watch next

The interim SOL-R Week 52 safety analysis is due in the fourth quarter of 2026, followed by the planned AXPAXLI NDA submission in the same quarter. Both are company-stated targets, not confirmed events.

Ocular said SOL-X enrollment continues and it plans to modify the open-label protocol to 48-week dosing based on SOL-1 durability, with the vast majority of investigators and eligible subjects choosing to participate. HELIOS-3, the Phase 3 non-proliferative diabetic retinopathy trial, is enrolling approximately 620 patients dosed every 12 months versus sham.

SOL-R topline results are targeted for the first quarter of 2028 after key secondary endpoints are evaluated. Ocular also said it appointed Riad Sherif to its board, overlapping with Seung Suh Hong until the end of this year.

Frequently Asked Questions

What does Ocular Therapeutix's Q3 2026 loss mean for retail investors?

The $94.8 million net loss, or $0.42 per share, reflects clinical spending rather than a revenue collapse. Revenue was $12.9 million against $74.8 million of R&D. For retail holders, the decisive figure is the $530.6 million cash balance, which the company says funds operations into 2028. That runway excludes the full cost of scaling manufacturing and a commercial team, so a future capital raise remains possible if AXPAXLI is approved.

What happens next for the AXPAXLI NDA?

The company said it will conduct an interim SOL-R Week 52 safety analysis in the fourth quarter of 2026, then submit the wet AMD NDA under the 505(b)(2) pathway in the same quarter. The submission would rest on SOL-1 Week 52 efficacy data, combined safety data exceeding 300 patients with at least one year of follow-up, and confirmatory evidence. Ocular said the pathway could shorten FDA review by up to 60 days.

Why did Ocular Therapeutix's R&D costs jump in Q3 2026?

The company attributed the rise to $74.8 million from $52.4 million to accelerated enrollment in the HELIOS-3 diabetic retinopathy study and the SOL-X long-term extension study, plus increased headcount and infrastructure for expanded trial activity. Selling and marketing also rose to $15.7 million from $13.1 million on pre-commercial preparation for a potential AXPAXLI launch, and general and administrative costs increased to $18.8 million from $16.0 million.

Bottom Line

Ocular's cash runway and Q4 2026 NDA target carry the story; the widening loss is the cost of getting there.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.